1
|
Bruno F, de Filippo O, Sardone A, Capranzano P, Conrotto F, Sheiban I, Giacobbe F, Laudani C, Burzotta F, Saia F, Escaned J, Raposeiras Roubin S, Mancone M, Templin C, Candreva A, Trabattoni D, Wanha W, Stefanini G, Chieffo A, Cortese B, Casella G, Wojakowski W, Colombo F, De Ferrari GM, Boccuzzi G, D'Ascenzo F, Iannaccone M. Long-term impact of intravascular ultrasound-guidance for percutaneous coronary intervention on unprotected left main. The IMPACTUS-LM, an observational, multicentric study. Int J Cardiol 2024; 401:131861. [PMID: 38365014 DOI: 10.1016/j.ijcard.2024.131861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 01/14/2024] [Accepted: 02/12/2024] [Indexed: 02/18/2024]
Abstract
INTRODUCTION The potential benefit on long term outcomes of Percutaneous Coronary Intervention (PCI) on Unprotected Left Main (ULM) driven by IntraVascular UltraSound (IVUS) remains to be defined. METHODS IMPACTUS LM-PCI is an observational, multicenter study that enrolled consecutive patients with ULM disease undergoing coronary angioplasty in 13 European high-volume centers from January 2002 to December 2015. Major Adverse Cardiovascular Events (MACEs) a composite of cardiovascular (CV) death, target vessel revascularization (TVR) and myocardial infarction (MI) were the primary endpoints, while its single components along with all cause death the secondary ones. RESULTS 627 patients with ULM disease were enrolled, 213 patients (34%) underwent IVUS-guided PCI while 414 (66%) angioguided PCI. Patients in the two cohorts had similar prevalence of risk factors except for active smoking and clinical presentation. During a median follow-up of 7.5 years, 47 (22%) patients in the IVUS group and 211 (51%) in the angio-guided group underwent the primary endpoint (HR 0.42; 95% CI [0.31-0.58] p < 0.001). After multivariate adjustment, IVUS was significantly associated with a reduced incidence of the primary endpoint (adj HR 0.39; 95% CI [0.23-0.64], p < 0.001), mainly driven by a reduction of TVR (ad HR 0.30, 95% CI [0.15-0.62], p = 0.001) and of all-cause death (adj HR 0.47, 95% CI [0.28-0.82], p = 0.008). IVUS use, age, diabetes, side branch stenosis, DES and creatinine at admission were independent predictors of MACE. CONCLUSIONS In patients undergoing ULM PCI, the use of IVUS was associated with a reduced risk at long-term follow-up of MACE, all-cause death and subsequent revascularization.
Collapse
Affiliation(s)
- Francesco Bruno
- Division of Cardiology, "Città della Salute e della Scienza di Torino" Hospital, Department of Medical Sciences, University of Turin, Turin 10126, Italy..
| | - Ovidio de Filippo
- Division of Cardiology, "Città della Salute e della Scienza di Torino" Hospital, Department of Medical Sciences, University of Turin, Turin 10126, Italy
| | - Andrea Sardone
- San Giovanni Bosco Hospital, ASL Città Torino, Turin, Italy
| | - Piera Capranzano
- Cardiology Division, Policlinico Hospital, University of Catania, Catania, Italy
| | - Federico Conrotto
- Division of Cardiology, "Città della Salute e della Scienza di Torino" Hospital, Department of Medical Sciences, University of Turin, Turin 10126, Italy
| | - Imad Sheiban
- Division of Cardiology, Peschiera del Garda Hospital, Verona, Italy
| | - Federico Giacobbe
- Division of Cardiology, "Città della Salute e della Scienza di Torino" Hospital, Department of Medical Sciences, University of Turin, Turin 10126, Italy
| | - Claudio Laudani
- Cardiology Division, Policlinico Hospital, University of Catania, Catania, Italy
| | - Francesco Burzotta
- Fondazione Policlinico Universitario A. Gemelli ICCS, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Francesco Saia
- Cardiology Unit, Cardio-Thoracic-Vascular Department, IRCCS University Hospital of Bologna, Bologna, Italy
| | - Javier Escaned
- Interventional Cardiology Unit, Hospital Clinico San Carlos IDISSC, Universidad Complutense de Madrid, Calle del Prof Martín Lagos, 28040 Madrid, Spain
| | | | - Massimo Mancone
- Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Roma
| | - Christian Templin
- University Heart Center, Department of Cardiology, University Hospital Zurich, and University of Zurich, Zurich, Switzerland
| | - Alessandro Candreva
- University Heart Center, Department of Cardiology, University Hospital Zurich, and University of Zurich, Zurich, Switzerland
| | | | - Wojciech Wanha
- Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
| | - Giulio Stefanini
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Humanitas Research Hospital IRCCS, Rozzano, Milan, Italy
| | - Alaide Chieffo
- Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy
| | - Bernardo Cortese
- Cardiovascular Research Center, Fondazione Ricerca e Innovazione Cardiovascolare, Milan, Italy
| | | | - Wojciech Wojakowski
- Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
| | | | - Gaetano Maria De Ferrari
- Division of Cardiology, "Città della Salute e della Scienza di Torino" Hospital, Department of Medical Sciences, University of Turin, Turin 10126, Italy
| | | | - Fabrizio D'Ascenzo
- Division of Cardiology, "Città della Salute e della Scienza di Torino" Hospital, Department of Medical Sciences, University of Turin, Turin 10126, Italy
| | | |
Collapse
|
2
|
Colangelo S, Sardone A, Colombo F, Boccuzzi G, Iannaccone M. Retrograde Fenestration of Covered Stent After Left Main–Left Anterior Descending Perforation. JACC Cardiovasc Interv 2022; 15:e227-e229. [DOI: 10.1016/j.jcin.2022.07.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Accepted: 07/19/2022] [Indexed: 11/06/2022]
|
3
|
Sardone A, Iannaccone M, Savio D, Colombo F, Di Maggio L, Colangelo S, Franchin L, Boccuzzi GG. [Percutaneous treatment of intermediate- and high-risk pulmonary embolism: two case reports]. G Ital Cardiol (Rome) 2022; 23:22S-24S. [PMID: 35848914 DOI: 10.1714/3838.38224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Pulmonary embolism is the third most common cause of cardiovascular emergency. Risk stratification is crucial in the clinical and therapeutic management of these patients. The latest European guidelines introduced a new classification based on short-term mortality risk stratification, dividing patients into four categories (high, intermediate-high, intermediate-low and low risk). Despite the limited evidence in this field, the percutaneous treatment of pulmonary embolism represents an option of interest; however, correct patient selection and device choice should be better investigated. In this article, we present two case reports of patients with intermediate-high-risk and high-risk pulmonary embolism treated with the EkoSonic Endovascular System (EKOS Corp., Bothell, WA, USA) and the FlowTriever System (Inari Medical, Irvine, CA, USA), respectively.
Collapse
Affiliation(s)
| | | | - Daniele Savio
- Radiologia Interventistica, Ospedale San Giovanni Bosco, ASL di Torino, Torino
| | | | - Luca Di Maggio
- Radiologia Interventistica, Ospedale San Giovanni Bosco, ASL di Torino, Torino
| | | | - Luca Franchin
- Radiologia Interventistica, Ospedale San Giovanni Bosco, ASL di Torino, Torino
| | | |
Collapse
|
4
|
Vizzari G, Grasso C, Sardone A, Mazzone P, Laterra G, Frazzetto M, Sacchetta G, Micari A, Tamburino C, Contarini M. Real-world experience with the new Watchman FLX device: Data from two high-volume Sicilian centers. The FLX-iEST registry. Catheter Cardiovasc Interv 2022; 100:154-160. [PMID: 35592941 DOI: 10.1002/ccd.30237] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2021] [Revised: 04/11/2022] [Accepted: 05/08/2022] [Indexed: 12/15/2022]
Abstract
INTRODUCTION The Watchman-FLX left atrial appendage closure (LAAC) device presents innovative features: higher conformability, reduced length, closed distal "flex-ball" during deployment, and flattened surface. We report our real-world experience with the Watchman-FLX device in two centers with consolidated LAAC expertise. METHODS We enrolled 200 consecutive Watchman-FLX patients (2019-2021) in a nonrandomized double-center registry; procedural data and follow-up for midterm clinical outcomes were collected. A control group of 100 patients treated with first-generation Watchman (2.5) was included. RESULTS According to mean CHAD2 DS2 -VASc (5 ± 1.40) and HAS-BLED (3.8 ± 1.01) scores, the population included in this study was at high risk: 29% had a previous stroke and 56.5% a bleeding event. Main LAAC indications were symptomatic hemorrhage (39.5%), need for triple antithrombotic therapy (39%), gastrointestinal bleeding (32%), and oral anticoagulation intolerance (18%). Transesophageal echocardiography guidance was followed in 93% of cases (48% in general anesthesia and 45% under conscious sedation). Repositioning an FLX device was required in 20% of cases and no complication occurred. In 96% of patients, the first selected device was delivered, while in 4% a device size change was required after the first choice (7% with Watchman 2.5). Peridevice leaks (<5 mm) were found postimplant in two cases (1%). Overall, the procedural success rate was 99.5%. One patient's procedure was unsuccessful (0.5%), due to left atrial appendage (LAA) anatomy; differently, the mean failure rate with Watchman 2.5 was 2%. No device embolization was reported. Complications (8.5%) were mainly related to the access site (3%); major bleedings (1%), and in-hospital death (0.5%) rarely occurred. After a follow-up of 272 ± 173 days, 2.3% of cases experienced a non-device-related stroke and 0.6% fatal bleeding. CONCLUSION Our registry showed a high procedural success rate of the Watchman-FLX in a high-risk population. According to our experience, the main advantages include easy implanting and repositioning, absence of embolization, good LAA sealing, and low rate of complications in the follow-up period.
Collapse
Affiliation(s)
- Giampiero Vizzari
- Department of Clinical and Experimental Medicine, A.O.U. Policlinic "G. Martino", University of Messina, Messina, Italy
| | - Carmelo Grasso
- Division of Cardiology, CAST "G. Rodolico", A.O.U. Policlinic "Vittorio Emanuele-San Marco", Catania, Italy
| | - Andrea Sardone
- Division of Cardiology, CAST "G. Rodolico", A.O.U. Policlinic "Vittorio Emanuele-San Marco", Catania, Italy
| | - Paolo Mazzone
- Department of Clinical and Experimental Medicine, A.O.U. Policlinic "G. Martino", University of Messina, Messina, Italy
| | - Giulia Laterra
- Department of Clinical and Experimental Medicine, A.O.U. Policlinic "G. Martino", University of Messina, Messina, Italy
| | - Marco Frazzetto
- Division of Cardiology, CAST "G. Rodolico", A.O.U. Policlinic "Vittorio Emanuele-San Marco", Catania, Italy
| | - Giorgio Sacchetta
- Cardiology Unit, "Umberto I" Hospital, ASP Siracusa, Siracusa, Italy
| | - Antonio Micari
- Department of Clinical and Experimental Medicine, A.O.U. Policlinic "G. Martino", University of Messina, Messina, Italy
| | - Corrado Tamburino
- Division of Cardiology, CAST "G. Rodolico", A.O.U. Policlinic "Vittorio Emanuele-San Marco", Catania, Italy
| | - Marco Contarini
- Cardiology Unit, "Umberto I" Hospital, ASP Siracusa, Siracusa, Italy
| |
Collapse
|
5
|
Iannaccone M, Nombela-Franco L, Gallone G, Annone U, Di Marco A, Giannini F, Ayoub M, Sardone A, Amat-Santos I, Fernandez-Lozano I, Barbero U, Dusi V, Toselli M, Petretta A, de Salvia A, Boccuzzi G, Colangelo S, Anguera I, D'Ascenzo F, Colombo A, De Ferrari GM, Escaned J, Garbo R, Mashayekhi K. Impact of successful chronic coronary total occlusion recanalization on recurrence of ventricular arrhythmias in implantable cardioverter-defibrillator recipients for ischemic cardiomyopathy (VACTO PCI study). Cardiovascular Revascularization Medicine 2022; 43:104-111. [DOI: 10.1016/j.carrev.2022.03.029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2022] [Revised: 03/22/2022] [Accepted: 03/28/2022] [Indexed: 12/11/2022]
|
6
|
Vizzari G, Mazzone P, Sardone A, Laterra G, Frazzetto M, Sacchetta G, Micari A, Tamburino C, Contarini M, Carmelo G. 637 Real-world experience with the new watchman FLX device: data from two high volume sicilian centres. The FLX-iest registry. Eur Heart J Suppl 2021. [DOI: 10.1093/eurheartj/suab134.055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Aims
Left Atrial Appendage closure (LAAC) represents a standard therapy for patients with Atrial Fibrillation and contraindication to oral anticoagulation (OAC). The ‘Watchman FLX’ presented innovative features: higher conformability to LAA shapes, reduced length of the device, closed ‘atraumatic’ distal end with ‘flex-ball’ shape during deployment, flattened covered external surface. We report the early ‘real-world’ experience with the innovative Watchman-FLX device, in two centres at high-procedural volume with consolidated LAAC experience.
Methods and results
From May 2019 to January 2021, we enrolled 200 consecutive patients treated with Watchman FLX in a non-randomized double-centre registry. We collected procedural data and followed up the patients for mid-term clinical outcomes. Mean age was 77 ± 7.18 years (67.5% male). Patients presented hypertension in 93% of cases, CKD in 57.5% (mean creatinine level 2 ± 1.1), Diabetes mellitus in 41.5%, Coronary artery disease and Heart failure in 55%. 29% had previous stroke and 56.5 bleeding events. Mean CHA2DS2-VASc was 5 ± 1.40 and HAS-BLED 4 ± 1.01. LAAC indication was: 39.5% of cases symptomatic Haemorrhage, 39% need for Triple antithrombotic therapy, 32% gastro-intestinal bleeding; 18% of patients presented OAC intolerance. TEE guidance was feasible in 186 cases (93%), of which 96 (48%) in general anesthesia and 90 (45%) in conscious sedation (MID-DEX) protocol. 14 ICE cases (7%) were performed in local anesthesia. FLX device repositioning after first attempt was required in 40 cases (20%) without any complication. Device size change, after first choice was needed in eight cases (4%). In one exceptional case simultaneous implant of two Watchman FLX devices was performed in a bi-lobed LAA. Peri-device leak was found in two cases (1%), one solved by changing FLX size (31 to 35 mm). Final procedural success was 99.5%; one unsuccessful case due to LAA reverse chicken-wing with very short depth; no device embolization. Six complications were related to access-site (3%), two cases of combined LAAC-Mitraclip procedure; two major bleedings occurred and one in-hospital death due to hemorrhagic shock (HAS-BLED = 6). At mean follow-up of 272 ± 172.76 days, only 2% of (non-device-related) stroke and 0.6% fatal bleeding resulted.
Conclusions
Our registry in a high-risk population treated with the innovative Watchman FLX device, showed high technical procedural success with easy implant and repositioning, no embolization, good LAA sealing and low rate of ischaemic/bleeding complications. 637 Figure
Collapse
Affiliation(s)
| | - Paolo Mazzone
- ‘G. Martino’ University Hospital, University of Messina, Italy
| | | | - Giulia Laterra
- ‘G. Martino’ University Hospital, University of Messina, Italy
| | | | | | - Antonio Micari
- ‘G. Martino’ University Hospital, University of Messina, Italy
| | | | | | | |
Collapse
|
7
|
Vizzari G, Contarini M, Mazzone P, Sardone A, Laterra G, Frazzetto MG, Sanfilippo M, Sacchetta G, Tamburino C, Micari A, Grasso C. TCT-238 Real-World Experience With the New Watchman FLX Device: Data From Two High-Volume Sicilian Centers: The FLX-IEST Registry. J Am Coll Cardiol 2021. [DOI: 10.1016/j.jacc.2021.09.1091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
8
|
Caggegi AM, Capranzano P, Scandura S, Mangiafico S, Castania G, Salerno T, Milici A, De Sanctis J, Bentivegna A, Frazzetto M, Sardone A, Di Salvo ME, Grasso C, Capodanno D, Tamburino C. Residual mitral regurgitation impact on outcomes after mitraclip therapy: five-year follow-up from the GRASP registry. Eur Heart J Cardiovasc Imaging 2021. [DOI: 10.1093/ehjci/jeaa356.220] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background – Although percutaneous mitral valve repair is an attractive alternative treatment option for patients with severe mitral regurgitation (MR) at high surgical risk, residual MR is commonly observed after the procedure and little is known about its impact on outcomes after MitraClip therapy, expecially in patients with severe left ventricular (LV) impairment.
Purpose – The aim of this prospective, observational study was to evaluate the impact of residual MR (MR ≤1+ vs. MR >1+) on long-term outcomes of mitral valve repair with the MitraClip System in high surgical risk patients presenting with moderate-to-severe or severe MR and with severe reduction of LV ejection fraction (EF).
Methods – Patients enrolled in the prospective Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation (GRASP) with functional MR and EF ≤30% who were eligible at almost five-year follow-up were included in the present analysis. The primary endpoint was death at 5-year follow-up. Also echocardiographic parameters at baseline and 5-year follow-up and rehospitalization rates were assessed.
Results – A total of 139 patients were included: 92 (66.2%) with post-procedural residual MR ≤1+ and 47 (33.8%) with residual MR > 1+ (41 patients with residual MR 2+, 5 with residual MR 3+, 1 with residual MR 4+). Comparable clinical and echocardiographic baseline characteristics were observed between the two groups except for NYHA functional class IV and implanted pace-maker (more frequent in patients with residual MR >1+) and previous myocardial infarction (more frequent in patients with residual MR ≤1+). At 5-year follow-up, no significant differences were reported in the primary endpoint (49.6% in patients with residual MR ≤ 1+ vs. 65.3% in patients with residual MR > 1+, p 0.203) and in cardiac death (37.8% in patients with residual MR ≤ 1+ vs. 42.6% in patients with residual MR > 1+, p 0.921). Cox regression analysis identified residual MR > 1+ as an independent predictor of re-hospitalization (HR 0.51, 95% CI 0.28-0.92, p =0.026). At 5-year follow-up, a significant reduction in left ventricular end-systolic volume was observed in patients with residual MR ≤ 1+.
Conclusions – At 5-year follow no significant differences in survival emerged in patients with severe LV dysfunction undergoing MitraClip therapy regardless residual MR. Nevertheless residual MR > 1+ emerged as an indipendent predictor of re-hospitalization.
Collapse
Affiliation(s)
- AM Caggegi
- University Policlinic of Catania, Catania, Italy
| | - P Capranzano
- University Policlinic of Catania, Catania, Italy
| | - S Scandura
- University Policlinic of Catania, Catania, Italy
| | - S Mangiafico
- University Policlinic of Catania, Catania, Italy
| | - G Castania
- University Policlinic of Catania, Catania, Italy
| | - T Salerno
- University Policlinic of Catania, Catania, Italy
| | - A Milici
- University Policlinic of Catania, Catania, Italy
| | - J De Sanctis
- University Policlinic of Catania, Catania, Italy
| | - A Bentivegna
- University Policlinic of Catania, Catania, Italy
| | - M Frazzetto
- University Policlinic of Catania, Catania, Italy
| | - A Sardone
- University Policlinic of Catania, Catania, Italy
| | - ME Di Salvo
- University Policlinic of Catania, Catania, Italy
| | - C Grasso
- University Policlinic of Catania, Catania, Italy
| | - D Capodanno
- University Policlinic of Catania, Catania, Italy
| | - C Tamburino
- University Policlinic of Catania, Catania, Italy
| |
Collapse
|
9
|
Capranzano P, Francaviglia B, Sardone A, Agnello F, Valenti N, Frazzetto M, Legnazzi M, Occhipinti G, Scalia L, Calvi V, Capodanno D, Tamburino C. Suitability for elderly with heart disease of a QR code-based feedback of drug intake: Overcoming limitations of current medication adherence telemonitoring systems. Int J Cardiol 2020; 327:209-216. [PMID: 33309634 DOI: 10.1016/j.ijcard.2020.12.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2020] [Revised: 11/10/2020] [Accepted: 12/02/2020] [Indexed: 02/03/2023]
Abstract
BACKGROUND Current medication adherence telemonitoring systems have several limitations prompting the need for simpler, low-cost and widely applicable tools. To meet these needs, we propose a novel method consisting in sending a digital feedback of medication intake by just reading a pre-defined Quick Response (QR) code attached on the pills box. METHODS To assess the potential clinical applicability of the proposed QR code-based task, its feasibility was tested among elderly with heart diseases. The primary endpoint was the learning success defined as a correct execution of all QR code-based digital task steps within 10 min. Study outcomes were compared between patients 65-75 years old (younger cohort) and those aged >75 years (older cohort) admitted to the Cardiology ward of a tertiary center. RESULTS A total of 262 patients were included: 128 (48.9%) were younger and 134 (51.1%) older. Despite a baseline low smartphone use in the overall population (41.2%), patients learning success of the digital task was as high as 75.6%, with lower rates among older vs. younger (67.9% vs. 83.6%, p = 0.005). After adjustment no significant independent association between age and success in learning the QR code-based task was found. Differently, increasing age was a negative independent predictor of smartphone use. The learning time was overall small, but longer in the older group (126 ± 100 vs. 100 ± 60 s, p = 0.03). CONCLUSIONS The QR code-based digital task was highly feasible for elderly with heart diseases suggesting its potential large-scale clinical application and encouraging the investigation of QR code-based systems for medication adherence telemonitoring.
Collapse
Affiliation(s)
- Piera Capranzano
- Division of Cardiology, Policlinico Hospital, University of Catania, Catania, Italy.
| | - Bruno Francaviglia
- Division of Cardiology, Policlinico Hospital, University of Catania, Catania, Italy
| | - Andrea Sardone
- Division of Cardiology, Policlinico Hospital, University of Catania, Catania, Italy
| | - Federica Agnello
- Division of Cardiology, Policlinico Hospital, University of Catania, Catania, Italy
| | - Noemi Valenti
- Division of Cardiology, Policlinico Hospital, University of Catania, Catania, Italy
| | - Marco Frazzetto
- Division of Cardiology, Policlinico Hospital, University of Catania, Catania, Italy
| | - Marco Legnazzi
- Division of Cardiology, Policlinico Hospital, University of Catania, Catania, Italy
| | - Giovanni Occhipinti
- Division of Cardiology, Policlinico Hospital, University of Catania, Catania, Italy
| | - Lorenzo Scalia
- Division of Cardiology, Policlinico Hospital, University of Catania, Catania, Italy
| | - Valeria Calvi
- Division of Cardiology, Policlinico Hospital, University of Catania, Catania, Italy
| | - Davide Capodanno
- Division of Cardiology, Policlinico Hospital, University of Catania, Catania, Italy
| | - Corrado Tamburino
- Division of Cardiology, Policlinico Hospital, University of Catania, Catania, Italy
| |
Collapse
|
10
|
Hagnäs MJ, Grasso C, Di Salvo ME, Sardone A, Rapisarda P, Pelliccia M, Dipasquale F, Castania G, Mangiafico S, Capranzano P, Barbanti M, Denaro A, Scandura S, Mäkikallio T, Capodanno D, Tamburino C. Effect of post-procedural evidence-based therapy on 2-year prognosis after transcatheter mitral valve repair. Eur J Heart Fail 2020; 23:677-679. [PMID: 32946191 DOI: 10.1002/ejhf.2002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Accepted: 09/10/2020] [Indexed: 12/28/2022] Open
Affiliation(s)
- Magnus J Hagnäs
- Department of Internal Medicine, Heart smithy, Lapland Central Hospital, Rovaniemi, Finland.,Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| | - Carmelo Grasso
- Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| | - Maria Elena Di Salvo
- Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| | - Andrea Sardone
- Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| | - Paola Rapisarda
- Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| | - Matteo Pelliccia
- Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| | - Francesco Dipasquale
- Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| | - Giuseppe Castania
- Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| | - Sarah Mangiafico
- Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| | - Piera Capranzano
- Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| | - Marco Barbanti
- Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| | - Alessandro Denaro
- Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| | - Salvatore Scandura
- Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| | - Timo Mäkikallio
- Division of Cardiology, Department of Internal Medicine, Oulu University Hospital, Oulu, Finland
| | - Davide Capodanno
- Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| | - Corrado Tamburino
- Cardiac-Thoracic-Vascular and Transplant Department, Azienda Ospedaliero-Universitaria 'Policlinico-Vittorio Emanuele', Catania, Italy
| |
Collapse
|